Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02092220 · ClinicalTrials.gov registry record · NA
A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas
A NA study of Diabetes Mellitus, Type 1, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT02092220 is a NA study of Diabetes Mellitus, Type 1 that has completed, run by Massachusetts General Hospital. The registered enrollment target is 48 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT02092220, a NA study of Diabetes Mellitus, Type 1, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes. Please note that all participants must work or attend school at one of the following campuses: Massachusetts General Hospital in Boston, MA; University of Massachusetts Medical Center in Worcester, MA; University of North Carolina in Chapel Hill, NC; Stanford University in Palo Alto, CA.
Conditions Studied
Interventions
- DEVICE Bionic Pancreas
- DEVICE Insulin pump with or without CGM
Study Locations (4)
Massachusetts
- Massachusetts General Hospital (MGH) Diabetes Research Center - Boston
- UMass Medical Center - Worcester
California
- Stanford University - Stanford
North Carolina
- University of North Carolina Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02092220
The ClinicalTrials.gov registry entry for NCT02092220 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (96% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Bionic Pancreas is the first listed.
NCT02092220 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02092220 about?
NCT02092220 is a clinical study titled "A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas". This study will test the hypothesis that a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults with type 1 diabetes. Please note that all participants must work or attend school at one of the follo...
What is the current status of trial NCT02092220?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2014-04. Estimated completion is 2016-12.
What conditions does trial NCT02092220 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT02092220?
The interventions under investigation include: Bionic Pancreas (DEVICE), Insulin pump with or without CGM (DEVICE).
Who is sponsoring clinical trial NCT02092220?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02092220 being conducted?
This trial has 4 study locations across California, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
-
Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes
RECRUITING · NA
-
National Institute of Diabetes and Digestive Kidney Diseases* Share Plus: Continuous Glucose Monitoring with Data Sharing in Older Adults with Type 1 Diabetes* and Their Care Partners to Improve Time in Range and Reduce Diabetes Distress.
RECRUITING · NA
-
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.